Companies › EIP Pharma
1 active drug program in 2 registered trials: 2 Phase 2; Neurology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Neflamapimod MAP kinase p38 alpha inhibitor | MAPK14 | Phase 2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA); Moderate to Severe Acute Ischaemic Stroke | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07033481 | Neflamapimod | Phase 2 | Nonfluent Variant Primary Progressive Aphasia (nfvPPA) | Neurology | Sep 2026 |
| NCT06987643 | Neflamapimod | Phase 2 | Moderate to Severe Acute Ischaemic Stroke | Neurology | Sep 2026 |
–
Aptinyx Neuron23 Bial R&D Investments SHINKEI Therapeutics NeuroTherapia
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.